Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells …
Y Vugmeyster, T Kikuchi, MA Lowes, F Chamian… - Clinical …, 2004 - Elsevier
Therapeutic administration of efalizumab, a humanized antibody to CD11a, induces a
marked but reversible increase of peripheral lymphocytes in psoriasis patients. In this study,
13 patients were treated with 12 weekly subcutaneous doses (2 mg/kg/week) of efalizumab,
and all 13 patients had increases in leukocyte counts. This increased white blood cell count
was mainly due to a 3-to 4-fold increase in the number of circulating CD3+ lymphocytes
during active treatment. Both naive and memory populations of CD4+ and CD8+ …
marked but reversible increase of peripheral lymphocytes in psoriasis patients. In this study,
13 patients were treated with 12 weekly subcutaneous doses (2 mg/kg/week) of efalizumab,
and all 13 patients had increases in leukocyte counts. This increased white blood cell count
was mainly due to a 3-to 4-fold increase in the number of circulating CD3+ lymphocytes
during active treatment. Both naive and memory populations of CD4+ and CD8+ …